PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.49%
R&D reduction while TRAW shows 42.46% growth. Joel Greenblatt would examine competitive risk.
-24.67%
G&A reduction while TRAW shows 43.55% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.97%
Operating expenses reduction while TRAW shows 42.84% growth. Joel Greenblatt would examine advantage.
-17.97%
Total costs reduction while TRAW shows 42.84% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.31%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
17.97%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
184.62%
Other expenses growth while TRAW reduces costs. John Neff would investigate differences.
18.43%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.43%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
58.16%
EPS growth while TRAW declines. John Neff would investigate advantages.
58.16%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
96.23%
Share count reduction below 50% of TRAW's 5.74%. Michael Burry would check for concerns.
96.23%
Diluted share reduction below 50% of TRAW's 5.74%. Michael Burry would check for concerns.